Key result
Elevated plasma sialic acids strongly predict CVD presence with an AUC of ~0.93.
Case-Control (n=60)
Answers are grounded in this paper and cite their sources.
Cardiovascular disease (CVD) is a group of health conditions affecting the heart and vascular system with very high prevalence and mortality rates. The presence of CVD is characterised by high levels of inflammation which have previously been associated with increased plasma concentrations of N -acetyl neuraminic acid (Neu5Ac). While Neu5Ac has been studied in the context of CVD, Neu5,9Ac 2 has not, despite being the second most abundant sialic acid in human plasma. A small-scale pilot study of thirty plasma samples from patients with diagnosed CVD, and thirty age and sex-matched healthy controls, was designed to gain insight into sialic acids as biomarkers for CVD and potential future areas of study. Each sample was assayed for Neu5Ac and Neu5,9Ac 2 concentrations. Mean Neu5Ac and Neu5,9Ac 2 concentrations were significantly elevated in patients with CVD compared to healthy controls (Neu5Ac: P < 0.001; Neu5,9Ac 2 : P < 0.04). Receiver operator curve (ROC) analysis indicated that both Neu5Ac and Neu5,9Ac 2 have reasonable predictive power for the presence of CVD (Neu5Ac AUC: 0.86; Neu5,9Ac 2 AUC: 0.71). However, while Neu5Ac had both good sensitivity (0.82) and specificity (0.81), Neu5,9Ac 2 had equivalent specificity (0.81) but very poor sensitivity (0.44). A combination marker of Neu5Ac + Neu5,9Ac 2 showed improvement over Neu5Ac alone in terms of predictive power (AUC: 0.93), sensitivity (0.87), and specificity (0.90). Comparison to a known inflammatory marker, high sensitivity c-reactive protein (hs-CRP: P-value: NS, ROC:0.50) was carried out, showing that both Neu5Ac and Neu5,9Ac 2 outperformed this marker. Further to this, hs-CRP values were combined with the three different sialic acid markers to determine any effect on the AUC values. A slight improvement in AUC was noted for each of the combinations, with Neu5Ac + Neu5,9Ac 2 + hs-CRP giving the best AUC of 0.97 overall. Thus, Neu5Ac would appear to offer good potential as a predictive marker for the presence of CVD, which the addition of Neu5,9Ac 2 predictive power improves, with further improvement seen by the addition of hs-CRP.
No takes yet. Share an insight, caveat, or question.
Cheeseman et al. (2023) conducted a case-control in Cardiovascular disease (n=60). Plasma Neu5Ac and Neu5,9Ac2 concentrations vs. Healthy controls and high-sensitivity C-reactive protein (hs-CRP) was evaluated on Predictive power for the presence of cardiovascular disease (ROC AUC) and mean biomarker elevation (AUC 0.86 (Neu5Ac); AUC 0.71 (Neu5,9Ac2); AUC 0.93 (Neu5Ac + Neu5,9Ac2); AUC 0.97 (Neu5Ac + Neu5,9Ac2 + hs-CRP), p=<0.001 (Neu5Ac); <0.04 (Neu5,9Ac2)). Plasma Neu5Ac and Neu5,9Ac2 were significantly elevated in CVD vs controls (P<0.001 and P<0.04) and together strongly predicted CVD presence (combined AUC 0.93; AUC 0.97 with hs-CRP).
Synapse has enriched 10 related papers. Consider them for comparative context: